CIK 0001590877
- Non-accelerated filer
- Smaller reporting company
REGENXBIO Inc.
Sign in to watch- Ticker
- RGNX
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Entity type
- Operating
- EIN
- 471851754
- Phone
- +1 240-552-8181
- Business address
- 9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD, 20850
- Former names
- ReGenX Biosciences, LLC
- Open-market buys, last 90 days
- $949,381
- in 1 filing
- Open-market sales, last 90 days
- $0
- in 0 filings
Net +$949,381. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2019-04-18 | Christmas Patrick J. SVP, General Counsel | Exercise or conversion · Employee Stock Option (Right to Buy) | −3,541 | 49,931 | ||
| 2019-04-18 | Christmas Patrick J. SVP, General Counsel | Exercise or conversion · Stock Option (Right to Buy) | −1,459 | 9,641 | ||
| 2019-04-17 | PAKOLA STEVE Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +95,000 | 95,000 | ||
| 2019-04-15 | Danos Olivier Chief Scientific Officer | Exercise or conversion | +2,000 | $20.35 | $41K | 8,500 |
| 2019-04-15 | Danos Olivier Chief Scientific Officer | Sale | −1,000 | $52.23 | $52K | 7,500 |
| 2019-04-15 | Danos Olivier Chief Scientific Officer | Sale | −1,000 | $53.09 | $53K | 6,500 |
| 2019-04-15 | Danos Olivier Chief Scientific Officer | Exercise or conversion · Stock Option (Right to Buy) | −2,000 | 71,500 | ||
| 2019-03-21 | Vasista Vittal Chief Financial Officer | Sale | −8,300 | $60.64 | $503K | 230,915 |
| 2019-03-21 | Vasista Vittal Chief Financial Officer | Sale | −1,700 | $61.31 | $104K | 229,215 |
| 2019-03-19 | Mills Kenneth T. President and CEO | Exercise or conversion | +15,000 | $0.85 | $13K | 261,000 |
| 2019-03-19 | Mills Kenneth T. President and CEO | Sale | −5,870 | $58.21 | $342K | 255,130 |
| 2019-03-19 | Mills Kenneth T. President and CEO | Sale | −9,130 | $58.74 | $536K | 246,000 |
| 2019-03-19 | Mills Kenneth T. President and CEO | Exercise or conversion · Employee Stock Option (Right to Buy) | −15,000 | 159,670 | ||
| 2019-03-12 | Danos Olivier Chief Scientific Officer | Exercise or conversion | +5,000 | $20.35 | $102K | 6,500 |
| 2019-03-12 | Danos Olivier Chief Scientific Officer | Exercise or conversion · Stock Option (Right to Buy) | −5,000 | 73,500 | ||
| 2019-03-05 | Vasista Vittal Chief Financial Officer | Sale | −3,068 | $60.01 | $184K | 239,215 |
| 2019-02-25 | Simpson Curran SVP, Product Development & CTO | Exercise or conversion | +5,300 | $35.80 | $190K | 44,800 |
| 2019-02-25 | Simpson Curran SVP, Product Development & CTO | Sale | −5,300 | $54.05 | $286K | 39,500 |
| 2019-02-25 | Simpson Curran SVP, Product Development & CTO | Exercise or conversion · Stock Option (Right to Buy) | −5,300 | 41,250 | ||
| 2019-02-15 | Mills Kenneth T. President and CEO | Sale | −3,412 | $45.96 | $157K | 257,588 |
Page 29 of 43 · 852 trades